Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients
Date Issued
2010-01-01
Author(s)
Siegler, Uwe
Jörger, Simon
Wodnar-Filipowicz, Aleksandra
DOI
10.3109/14653241003786155
Abstract
Alloreactive natural killer (NK) cells are potent effectors of innate anti-tumor defense. The introduction of NK cell-based immunotherapy to current treatment options in acute myeloid leukemia (AML) requires NK cell products with high anti-leukemic efficacy optimized for clinical use.